Pharmacy

The FINANCIAL -- Eli Lilly and Company on April 4 announced top-line results from its Phase 3 REACH-2 study of CYRAMZA (ramucirumab) as a single agent in the second-line treatment of people with hepatocellular carcinoma (HCC), also known as liver ...

More Articles ...

More Articles ...

The FINANCIAL -- Roche announced on March 13 that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting ...

The FINANCIAL -- Amgen on March 29 announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO (blinatumomab) for the ...

Videos

Watch the video